MedTrace Logo

Bioequivalence Study betweenYHP2407 and YHR2502 in Healthy Subjects

NCT06926387 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2025-05-13

No results posted yet for this study

Summary

A randomized, open-label, single-dose, 2-sequence, 2-period, crossover clinical trial to investigate the bioequivalence between YHP2407 and YHR2502 in healthy volunteers

Conditions

  • Healthy Volunteer

Interventions

DRUG

YHP2407

Test drug: YHP2407, Comparator: YHR2502

DRUG

YHR2502

Test drug: YHP2407, Comparator: YHR2502

Sponsors & Collaborators

  • Yuhan Corporation

    lead INDUSTRY

Principal Investigators

  • Hyejin Lim · Gimpo Woori Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-04-17
Primary Completion
2025-04-19
Completion
2025-04-29

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06926387 on ClinicalTrials.gov